Information about Fosinopril
Fosinopril is an angiotensin-converting enzyme (ACE) inhibitor used in the therapy of hypertension and heart failure.
Liver safety of Fosinopril
Fosinopril is associated with a low rate of transient serum aminotransferase elevations during therapy and has been linked to rare instances of acute liver injury.
Mechanism of action of Fosinopril
Fosinopril (fos sin' oh pril) is an ACE inhibitor approved for use alone or in combination with other agents as therapy of hypertension and heart failure. Like other ACE inhibitors, fosinopril inhibits the conversion of angiotensin I, a relatively inactive molecule, to angiotensin II which is the major mediator of vasoconstriction and volume expansion induced by the renin-angiotensin system. Other enzymes besides that which converts angiotensin I to II may also be inhibited, which may account for some of the dose related side effects of the ACE inhibitors.
FDA approval information for Fosinopril
Fosinopril was approved for use in the United States in 1991 and is available in 10, 20 and 40 mg tablets in generic forms and under the trade name Monopril.
Dosage and administration for Fosinopril
The typical dose in adults is 10 mg once daily initially, with gradual adjustment based upon blood pressure response and tolerance. The usual maintenance dosage is 20 to 40 mg daily and the maximum 80 mg in one or two divided doses administered long term. Fosinopril is also available in fixed combinations with hydrochlorothiazide (Monopril HCT).
Side effects of Fosinopril
Common side effects include dizziness, fatigue, headache, cough, gastrointestinal upset and skin rash.
Common ACE inhibitors include the following: